Publications by authors named "Lorrin Yee"

Claim this Profile
H
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
Emiliano Calvo, Analia Azaro, Jordi Rodon, Luc Dirix, Manon Huizing, Lorrin Yee

Invest New Drugs· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Irene Brana, Antonio Calles, Patricia M LoRusso, Lorrin K Yee, Thomas A Puchalski

Target Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Charles S Fuchs, Marwan Fakih, Lee Schwartzberg, Allen L Cohn, Lorrin Yee

Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Patricia LoRusso, Pasi A Jänne, Moacyr Oliveira, Naiyer Rizvi, Lisa Malburg, Lorrin Yee

Clin Cancer Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Monica M Mita, Matthew A Spear, Lorrin K Yee, Alain C Mita, Elisabeth I Heath

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Lee Schwartzberg, Ronald Burkes, Barry Mirtsching, Timothy Rearden, Peter Silberstein, Lorrin Yee

BMC Cancer· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Peter J Rosen, Christopher J Sweeney, Dorothy J Park, Darrin M Beaupre, Hongjie Deng, Lorrin K Yee

Clin Cancer Res· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
David I Quinn, John Nemunaitis, Jyotsna Fuloria, Carolyn D Britten, Nashat Gabrail, Lorrin Yee

Clin Pharmacokinet· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Julio Hajdenberg, Thomas Grote, Lorrin Yee, Roberto Arevalo-Araujo, Laurie A Latimer

J Support Oncol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
Frank M Senecal, Lorrin Yee, Nashat Gabrail, Veena Charu, Dianne Tomita

Clin Breast Cancer· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Lee S Schwartzberg, Lorrin K Yee, Frank M Senecal, Veena Charu, Dianne Tomita

Oncologist· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Paul J Hesketh, Francis Arena, Dhimant Patel, Matt Austin, Paul D'Avirro, Lorrin K Yee

Cancer· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis